Cirrhosis News and Research

Latest Cirrhosis News and Research

Understanding HCV disease progression rates among PWID

The Hepatitis C virus (HCV) infection is a chronic blood-borne viral infection that affects an estimated 160 million people, or 2-3% of the population world-wide. Alarmingly, chronic HCV infection accounts for one-quarter of the cases of cirrhosis and hepatocellular carcinoma (HCC). If HCV is left untreated, chronic liver disease will occur in 60-70% of the cases, cirrhosis in 5-20% of the cases, and 1-5% will die from decompensated cirrhosis or HCC.

6 Oct 2015

New trial results show efficacy of novel enzyme-replacement therapy for genetic lipid disorder

Of the more than 50 known lysosomal storage diseases (LSDs)-rare inherited metabolic disorders-only seven can be treated with approved enzyme-replacement therapies.

10 Sep 2015

Researchers identify new virus that plays role in rare type of liver cancer

More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus.

28 Aug 2015

Yale study identifies new barrier to caring for chronic hepatitis C patients

Nearly one in four patients with chronic hepatitis C (HCV) are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study.

27 Aug 2015

Multi-national group of scientists developing new test for Hepatocellular Carcinoma

A group of clinicians and geochemists are working to develop a test for the most common form of primary liver cancer, HCC (Hepatocellular Carcinoma). HCC kills over 600,000 people worldwide every year.

19 Aug 2015

Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed

The number of hepatitis C patients suffering from advanced liver damage may be grossly underestimated and underdiagnosed, according to a study led by researchers at Henry Ford Health System and the U.S. Centers for Disease Control and Prevention.

19 Aug 2015

UC San Diego researchers discover cells that regenerate better liver tissue than ordinary liver cells

The mechanisms that allow the liver to repair and regenerate itself have long been a matter of debate. Now researchers at University of California, San Diego School of Medicine have discovered a population of liver cells that are better at regenerating liver tissue than ordinary liver cells, or hepatocytes.

14 Aug 2015

Breath analysis shows potential biomarkers for early-stage diagnosis of liver disease

A natural compound called limonene, which is found in oranges and lemons, could be indicative in early-stage diagnosis of liver disease, according to research published in the journal EBioMedicine by researchers in the Molecular Physics Group at the University of Birmingham.

12 Aug 2015

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care had examined their added benefit in a dossier assessment completed in April 2015.

7 Aug 2015

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Adults who are worried or terrified sometimes curl up into a fetal position. Likewise, adult cells that are injured, including genetic injury leading to cancer, initiate a process that was present during embryonic development.

4 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Weight loss through lifestyle modifications, bariatric surgery can reduce features of NASH

Weight loss through both lifestyle modification and bariatric surgery can significantly reduce features of nonalcoholic steatohepatitis (NASH), a disease characterized by fat in the liver, according to two new studies published in Gastroenterology, the official journal of the American Gastroenterological Association.

28 Jul 2015

Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

Resistance training in the gym leads to a fall in liver fat levels. This is the finding of a new study held at the University of Haifa in cooperation with Tel Aviv Medical Center and Tel Aviv University.

28 Jul 2015

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Nutrition Science Initiative has launched the first-ever randomized, controlled clinical trial to determine whether removing added sugars from the diet can halt or even reverse nonalcoholic fatty liver disease (NAFLD) in children.

16 Jul 2015

Diabetes drug metformin can also treat portal hypertension

The diabetes drug metformin continues to expand beyond its treatment for type 2 diabetes. In addition to its potential use in treating age-related health problems, metformin can treat portal hypertension—high blood pressure in the liver resulting from cirrhosis, according to a new study in American Journal of Physiology—Gastrointestinal and Liver Physiology.

15 Jul 2015

dlDNA marks progression of HBV-related liver disease

The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut.

30 Jun 2015

Hiroshima University researchers develop accurate method to detect drug resistant HCV mutation

A rapid, sensitive, and accurate method to detect drug resistant hepatitis C virus (HCV) mutants has been developed. Researchers at Hiroshima University established a system to rapidly and accurately measure the presence of HCV Y93H drug resistant mutant strains, and evaluate the proportion of patients harboring this mutation prior to treatment.

29 Jun 2015

AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

The American Association for the Study of Liver Diseases, in partnership with the Infectious Diseases Society of America and in collaboration with the International Antiviral Society-USA, created online Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 to aid practitioners treating patients infected with hepatitis C virus (HCV).

26 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

New book examines all aspects of HBV and HDV infections

Despite the availability of an effective vaccine for hepatitis B, hundreds of millions of people worldwide are infected with the hepatitis B virus (HBV). This virus can cause serious liver damage and cancer in chronically infected patients. Hepatitis delta virus (HDV), a satellite of HBV, can exacerbate the disease.

19 Jun 2015

Cirrhosis News and Research

Latest Cirrhosis News and Research

Understanding HCV disease progression rates among PWID

New trial results show efficacy of novel enzyme-replacement therapy for genetic lipid disorder

Researchers identify new virus that plays role in rare type of liver cancer

Yale study identifies new barrier to caring for chronic hepatitis C patients

Multi-national group of scientists developing new test for Hepatocellular Carcinoma

Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed

UC San Diego researchers discover cells that regenerate better liver tissue than ordinary liver cells

Breath analysis shows potential biomarkers for early-stage diagnosis of liver disease

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Weight loss through lifestyle modifications, bariatric surgery can reduce features of NASH

Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Diabetes drug metformin can also treat portal hypertension

dlDNA marks progression of HBV-related liver disease

Hiroshima University researchers develop accurate method to detect drug resistant HCV mutation

AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

New book examines all aspects of HBV and HDV infections

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cirrhosis News and Research

Latest Cirrhosis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in